Human CD40‐ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production

Gauchat, Jean‐François; Aubry, Jean‐Pierre; Mazzei, Gonzalo J.; Life, Paul; Jomotte, Therese; Elson, Greg; Bonnefoy, Jean‐Yves

doi:10.1016/0014-5793(93)81175-y

Cited by 127 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The similar immunology crossreactivity was confirmed for the porcine, mouse and human CD154 (Wienhold et al, 2002, Gauchat et al, 1993, Maliszewski et al, 1993, Fanslow et al, 1994 CD154 is expressed on T cells following activation (Castle et al, 1993) and has a critical role in the generation on of both cells mediated and humoral immune responses, as well as regulation of antigen presenting cell activity (van Kooten and Banchereau, 2000). Several studies on the interactions between CD40 and CD154 have contributed extensively to our understanding of how both humoral and cellular immune responses are regulated (Grewal and Flavell., 1998).…”

Section: Discussionsupporting

confidence: 64%

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Olędzka

Kay

et al. 2007

Molecular Immunology

View full text Add to dashboard Cite

The CD154 (CD40 ligand) molecule is a member of the tumor necrosis factor (TNF) family and plays an important role in the interaction between antigen-specific lymphocytes and antigen-presenting cells. In this study, reverse transcription-PCR cloning was used to derive the sequence encoding ovine CD154. Sequence analysis of the cloned CD154 gene showed a similarity of 97, 89 and 88% with the bovine, porcine and human sequences, respectively, at the nucleic acid level. The deduced amino acid sequence for the ovine CD154

show abstract

Section: Discussionsupporting

confidence: 64%

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Olędzka

Kay

et al. 2007

Molecular Immunology

View full text Add to dashboard Cite

show abstract

“…5 By comparison, CD154 is expressed transiently on activated leukocytes, including mature CD4 + T cells, CD8 + T-cell subsets, and g T cells; and mast cells, eosinophils, and IL-2 activated NK cells. 6 CD154 also has been detected in purified monocytes, activated B cells, epithelial and vascular endothelial cells, smooth muscle cells, and DCs, although the in vivo relevance of CD154 expression in these cell types has not been clearly defined. 3 The CD40 and CD154 receptor ligand pair is classified correspondingly as members of the tumor necrosis factor receptor (TNF -R ) and TNF family of molecules, respectively.…”

Section: Cd40 Expression and Function In Human Cellsmentioning

confidence: 99%

Prospects for CD40-directed experimental therapy of human cancer

2002

View full text Add to dashboard Cite

CD40, a member of the tumor necrosis factor receptor ( TNF -R ) family, is a surface receptor best known for its capacity to initiate multifaceted activation signals in normal B cells and dendritic cells ( DCs ). CD40 -related treatment approaches have been considered for the experimental therapy of human leukemias, lymphomas, and multiple myeloma, based on findings that CD40 binding by its natural ligand ( CD40L ), CD154, led to growth modulation of malignant B cells. Recent studies also exploited the selective expression of the CD40 receptor on human epithelial and mesenchymal tumors but not on most normal, nonproliferating epithelial tissues. Ligation of CD40 on human breast, ovarian, cervical, bladder, non small cell lung, and squamous epithelial carcinoma cells was found to produce a direct growth -inhibitory effect through cell cycle blockage and / or apoptotic induction with no overt side effects on their normal counterparts. CD154 treatment also heightened tumor rejection immune responses through DC activation, and by increasing tumor immunogenicity through up -regulation of costimulatory molecule expression and cytokine production of epithelial cancer cells. These immunopotentiating features can produce a ''bystander effect'' through which the CD40 -negative tumor subset is eliminated by activated tumor -reactive cytotoxic T cells. However, the potential risk of systemic inflammation and autoimmune consequences remains a concern for systemic CD154 -based experimental therapy. The promise of CD154 as a tumor therapeutic agent to directly modulate tumor cell growth, and indirectly activate antitumor immune response, may depend on selective and / or restricted CD154 expression within the tumor microenvironment. This may be achieved by inoculating cancer vaccines of autologous cancer cells that have been transduced ex vivo with CD154, as documented by recently clinical trials. This review summarizes recent findings on CD154 recombinant protein -and gene therapy -based tumor treatment approaches, and examines our understanding of the multifaceted molecular mechanisms of CD154 -CD40 interactions.

show abstract

“…The first signal, given by IL-4 or IL-13, induces the expression of the ⑀ germline transcript (18 -20) and of some cell surface molecules involved in IgE and IgG4 synthesis such as CD23 (24 -29) or CD40L (30). The second signal, provided by the engagement of CD40 by CD40L or by an anti-CD40 mAb, induces the expression of the productive ⑀ transcript encoding for IgE (20 -23).…”

mentioning

confidence: 99%

CD86 (B7-2) on Human B Cells

Jeannin¹,

Delneste²,

Lecoanet‐Henchoz³

et al. 1997

Journal of Biological Chemistry

Self Cite

115

View full text Add to dashboard Cite

Immunoglobulin (Ig) E production by B cells requires two primary signals provided by T cells, interleukin (IL)-4 or IL-13 and CD40 ligand (CD40L).An efficient activation of T cells requires the engagement of the T cell receptor with the antigen-major histocompatibility complex and the engagement of appropriate costimulatory signals. A potent pathway of costimulation is the one involving the interaction of CD28 and CTLA-4 on T cells with their ligands CD80 (B7-1) and CD86 (B7-2) expressed by numerous antigenpresenting cells, including B cells (1-7).

show abstract

Human CD40‐ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production

Cited by 127 publications

References 34 publications

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Prospects for CD40-directed experimental therapy of human cancer

CD86 (B7-2) on Human B Cells

Contact Info

Product

Resources

About